In current smokers with COPD, LABA+LAMA is superior to LABA+ICS, regardless of blood eosinophils. Data from the FLAME trial. - Vienna 2024

New frontiers in chronic obstructive pulmonary disease treatment and management

Chair(s): Pradeesh Sivapalan, Lies Lahousse

Session type: Poster session

In current smokers with COPD, LABA+LAMA is superior to LABA+ICS, regardless of blood eosinophils. Data from the FLAME trial.

Alexander Mathioudakis

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Exploring effects of mechanical stress in the development of emphysema using a lung organoid

Arthur Pavot

Poster

Abstract

Effect of n-acetylcysteine against mucus hypersecretion in COPD

Paola Rogliani

Poster

Abstract

Mucus plugging and mucolytics in patients admitted with acute exacerbation of chronic obstructive pulmonary disease (COPD); investigating impact on short term mortality

Emad Abugassa

Poster

Abstract

Ketoprofen Lysinate exerts anti-inflammatory activity and preserves barrier function in injured primary bronchial epithelial cells

Maria Ferraro

Poster

Abstract

Machine learning models for different outcomes to better understand individual treatment response on COPD exacerbations in the IMPACT study

Helene Huts

Poster

Abstract

Efficacy of Budesonide/Glycopyrronium/Formoterol FDC across blood eosinophil ranges in Indian COPD patients: post-hoc analysis of a phase-IV clinical-trial

Priti Meshram

Poster

Abstract

The mitochondrial-targeted antioxidant SkQ1 ameliorates cigarette smoke-induced oxidative stress and airway inflammation

Jiangyue Qin

Abstract

In current smokers with COPD, LABA+LAMA is superior to LABA+ICS, regardless of blood eosinophils. Data from the FLAME trial.

Alexander Mathioudakis

Poster

Abstract

Sputum cytokine repeatability in COPD

Alex Mulvanny

Poster

Abstract

Pharmacological characterization of the relaxant effect of RCD405 in isolated human small airways

Luigino Calzetta

Abstract

Safety, Tolerability and Pharmacokinetics of The Phosphodiesterase 3/4 (PDE3/4) Inhibitor TQC3721 Suspension for Inhalation in Healthy Adult Subjects

Weiguo Li

Poster

Abstract

Impact of ensifentrine on trough FEV1 in COPD: a meta-analysis

Luigino Calzetta

Abstract

Efficacy of alvelestat on SGRQ in patients with alpha-1 antitrypsin deficiency and mild airflow limitation: A pooled analysis from two Phase 2 studies

James Fettiplace

Poster

Abstract

Ensifentrine treatment improves COPD symptoms and quality of life in a pooled analysis of the ENHANCE trials

Alexander Mathioudakis

Poster

Abstract

Efficacy and safety of ensifentrine in European patients with moderate to severe COPD: pooled results from the ENHANCE trials

Frits M.e. Franssen

Poster

Abstract

Ensifentrine improved symptoms and reduced moderate/severe exacerbation rate and risk in patients with COPD and significant cough and sputum

Victor Kim

Poster

Abstract

Clinical burden of disease in COPD patients on double and triple therapy – a retrospective, longitudinal German claims study

Roland Buhl

Poster

Abstract

Real-world safety of budesonide/glycopyrrolate/formoterol in Chinese patients with chronic obstructive pulmonary disease

Yongchang Sun

Poster

Abstract

Late Breaking Abstract - Phase 2 trial of HSK31858, a novel DPP1 inhibitor, in bronchiectasis

Weijie Guan

Poster

Abstract

CDN Connection Issue

The ERS Congress 2024, Vienna

#{title}